14 citations,
March 2022 in “Journal of inflammation research” Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
14 citations,
January 2020 in “Mediterranean Journal of Rheumatology” New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
10 citations,
November 2018 in “Nature Biotechnology” Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.
7 citations,
December 2019 in “American Journal of Clinical Dermatology” Topical therapies show promise for hair loss and acne treatment with minimal side effects.
May 2024 in “Aktualʹnì problemi sučasnoï medicini: Vìsnik Ukraïnsʹkoï medičnoï stomatologìčnoï akademì” Spironolactone and clascoterone are promising acne treatments with fewer side effects.
185 citations,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
17 citations,
January 2019 in “Journal of cutaneous medicine and surgery” JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
April 2024 in “Bioactive materials” New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.
15 citations,
January 2022 in “Journal of Infection” COVID-19 vaccines are safe and highly effective for children, with inactivated vaccines being slightly better.
4 citations,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
2 citations,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations,
September 2023 in “Stem cell research & therapy” Mesenchymal stem cells could help treat aging-related diseases better than current methods.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
5 citations,
May 2020 in “Clinical and Experimental Dermatology” Clascoterone may be a promising treatment for hair loss.
4 citations,
September 2012 in “Clinical Pharmacology in Drug Development” Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.
1 citations,
June 2017 in “International Journal of Toxicology” Most drugs fail to reach the market, but understanding their properties and using strategies like early toxicity tests and drug repurposing can help advance their development.
August 2024 in “JAMA Dermatology” Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
56 citations,
January 2021 in “Clinical and Experimental Medicine” The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
2 citations,
March 2016 in “The Journal of Dermatology” The Facial Psoriasis Log-based Area and Severity Index is a more effective way to measure improvements in facial psoriasis than the traditional method.
2 citations,
October 2015 in “Human Gene Therapy” The congress highlighted new gene therapy techniques and cell transplantation methods for treating diseases.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
79 citations,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
60 citations,
September 2013 in “Alimentary Pharmacology & Therapeutics” Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
51 citations,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.